MedTrace Logo

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

NCT03186378 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-08-11

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.

Conditions

  • Molluscum Contagiosum

Interventions

COMBINATION_PRODUCT

VP-102 with applicator

Subjects will receive treatment to their molluscum contagiosum with VP-102.

Sponsors & Collaborators

  • Paidion Research, Inc.

    collaborator INDUSTRY

  • Database Integrations, Inc.

    collaborator INDUSTRY

  • Cato Research

    collaborator INDUSTRY

  • Instat Services

    collaborator INDUSTRY

  • Verrica Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Goldenberg, MD · Verrica Pharmaceuticals Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-08
Primary Completion
2018-06-25
Completion
2018-06-25
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03186378 on ClinicalTrials.gov